ArticleACR open rheumatology2026
Cerebral Pain Processing Following TNFα Inhibitor Treatment in Rheumatoid Arthritis: A Randomized Double-Blind Placebo-Controlled fMRI Study.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study investigated the effects of tumor necrosis factor α (TNFα) blockade treatment, adalimumab (ADA), on cerebral pain processing in relevant brain regions in patients with rheumatoid arthritis (RA). Its secondary aim was to identify pretreatment markers in cerebral pain processing that might predict treatment response.
methodsA total of 25 patients with RA were randomly allocated treatment with 40 mg ADA (n = 14) or placebo (PBO) (n = 11) injected subcutaneously. During functional magnetic resonance imaging (fMRI), patients underwent individually calibrated pressure-pain stimulation on the most inflamed interphalangeal joint and on an unaffected control site before and after four weeks of treatment.
resultsThe ADA but not the PBO group showed significant changes in subjective, clinician-rated, and objective measures. Both groups exhibited significant activations in pain-relevant brain regions during the fMRI task. Cerebral activations did not change following treatment nor did they correlate pre- or post-treatment with changes in systemic inflammation (measured as the change in erythrocyte sedimentation rate [ΔESR]). Baseline cerebral activations did not correlate with treatment response in terms of ΔESR nor with pain or fatigue outcomes. However, in an exploratory analysis, five baseline activation clusters in the ADA group, and one in the PBO group, correlated positively with changes in swollen joint count (P < 0.001).
conclusionsOur study did not observe any associations between treatment with TNFα inhibitors and changes in cerebral pain processing, indicating that this treatment may not have a clear central effect.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.